Table 2.
Cox survival analysis
| HR | 95% CI | p | % fraction of global R2 | Bootstrap Inclusion Frequency (%) | Linearity Stability (%) | Interaction with gender | |||
|---|---|---|---|---|---|---|---|---|---|
| Lower | Higher | HR | p | ||||||
| Age (referred to 10 years) | 2.26 | 1.799 | 2.840 | ≤0.001 | 46.6 | 100 | 82.0 | 0.994 | 0.559 |
| Gender (referred to male) | 0.43 | 0.299 | 0.561 | ≤0.001 | 14.6 | 99.9 | NA | — | — |
| BMI (kg/m2) | 0.90 | 0.755 | 1.073 | 0.24 | 56.4 | NA | 1.004 | 0.780 | |
| Waist circumference (cm) | 1.1 | 0.666 | 1.818 | 0.71 | 41.2 | NA | 1.000 | 0.922 | |
| Drugs number | 1.57 | 1.093 | 2.047 | ≤0.001 | 25.8 | 98.7 | 98.6 | 0.876 | 0.432 |
| Hypertension (referred to no Hypertension) | 0.85 | 0.701 | 1.032 | 0.10 | 8.7 | NA | 0.916 | 0.606 | |
| Diabetes (referred to no Diabetes) | 1.3 | 0.989 | 1.709 | 0.06 | 55.7 | NA | 0.791 | 0.125 | |
| CAD (referred to no CAD) | 1.1 | 0.709 | 1.705 | 0.67 | 14.4 | NA | 1.68 | 0.111 | |
| CHF (referred to no CHF) | 1.25 | 0.982 | 1.592 | 0.07 | 69.0 | NA | 0.761 | 0.144 | |
| COPD (referred to no COPD) | 1.1 | 0.942 | 1.285 | 0.23 | 10.5 | NA | 0.804 | 0.055 | |
| CKD (referred to no CKD) | 0.9 | 0.607 | 1.334 | 0.6 | 12.7 | NA | 1.191 | 0.533 | |
| Neurol. disease (referred to no Neurol disease) | 1.1 | 0.904 | 1.338 | 0.34 | 22.2 | NA | 0.891 | 0.462 | |
| Frailty (referred to no Frailty) | 1.02 | 0.771 | 1.351 | 0.89 | 13.0 | 91.2 | NA | 1.92 | ≤0.001 |
HR, Hazard Ratio; 95% CI, 95% Coefficient Interval; R2 = explained variance. BMI, Body Mass Index; CAD, Coronary Artery Disease; CHF, Chronic Heart Failure; COPD, Chronic Obstructive Pulmonary Disease; CKD, Chronic Kidney Disease; Neurol. disease, Neurological disease. NS = Not Significant. NA = Not Applicable.